NeuroSense shares surge 12.96% premarket after positive Phase 2 safety data for Alzheimer's drug PrimeC shows no serious adverse events.

NeuroSense Therapeutics (NRSN) surged 12.96% in premarket trading following the announcement of favorable safety and tolerability results from its Phase 2 NST-AD-001 study of PrimeC in Alzheimer’s disease. The company reported no serious adverse events and no unexpected safety signals, reinforcing the drug’s potential as a combination therapy targeting multiple disease mechanisms. As an exploratory proof-of-concept trial, the study’s descriptive clinical outcomes will be further analyzed with biomarker data, with comprehensive results expected in Q1 2026. The positive safety profile and alignment with unmet needs in Alzheimer’s disease treatment likely drove the sharp premarket rally.